{"organizations": [], "uuid": "3674adc146f0529aa865e2a9c5ce0b2789addbf3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-g1-therapeutics-announces-positive/brief-g1-therapeutics-announces-positive-trilaciclib-phase-2a-topline-data-showing-robust-myelopreservation-benefits-in-patients-with-small-cell-lung-cancer-idUSFWN1QN05G", "country": "US", "domain_rank": 408, "title": "BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-03-05T19:31:00.000+02:00", "replies_count": 0, "uuid": "3674adc146f0529aa865e2a9c5ce0b2789addbf3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-g1-therapeutics-announces-positive/brief-g1-therapeutics-announces-positive-trilaciclib-phase-2a-topline-data-showing-robust-myelopreservation-benefits-in-patients-with-small-cell-lung-cancer-idUSFWN1QN05G", "ord_in_thread": 0, "title": "BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - G1 Therapeutics Inc:\n* G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER\n* G1 THERAPEUTICS - CURRENTLY CONDUCTING TWO ADDITIONAL CLINICAL TRIALS OF TRILACICLIB WITH PRELIMINARY DATA FROM BOTH EXPECTED IN Q4 2018\n* G1 THERAPEUTICS - TRILACICLIB REDUCED CLINICALLY RELEVANT CONSEQUENCES OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION VERSUS PLACEBO\n* G1 THERAPEUTICS INC - STATISTICALLY SIGNIFICANT RESULTS FROM PHASE 2A TRIAL EVALUATING TRILACICLIB Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T19:31:00.000+02:00", "crawled": "2018-03-06T22:05:27.006+02:00", "highlightTitle": ""}